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Background. Disease severity and outcome in community-acquired pneumonia (CAP) depend on the host and on the challenge 
of the causal microorganism(s). We measured levels of immunoglobulins (Igs) and complement in 257 hospitalized adults with 
CAP and examined the association of low levels of Igs or complement to microbial etiology, disease severity, and short-term and 
long-term outcome.
Methods. Serum Igs were analyzed in blood samples obtained at admission and at 6 weeks postdischarge if admission levels were 
low. Serum complement deficiencies were screened with a total complement activity enzyme-linked immunosorbent assay (ELISA), 
with further analyzes performed if justified. Disease severity was assessed by the CURB-65 severity score. Short-term outcome was 
defined as a composite end point of intensive care unit (ICU) admission and 30-day mortality, and long-term outcome as 5-year 
all-cause mortality.
Results. At admission, 87 (34%) patients had low levels of at least 1 Ig, with low IgG2 as the most prevalent finding (55/21%). 
IgG levels were lower in bacterial than viral CAP (8.48 vs 9.97 g/L, P = .023), but low Igs were not associated with microbial etiology. 
Fifty-five (21%) patients had low lectin pathway activity, of which 33 (13%) were mannose-binding lectin (MBL) deficient. Low ad-
mission levels of any Ig or MBL were not associated with disease severity, short-term outcome, or long-term outcome. Excluding 
patients defined as immunocompromised from analysis did not substantially affect these results.
Conclusion. In hospitalized adults with CAP, low admission levels of Igs or complement were in general not associated with 
microbial etiology, disease severity, short-term outcome, or long-term outcome.
Keywords. complement; etiology; immunoglobulin; mannose-binding lectin; mannose-binding protein-associated serine pro-
teases; mortality; pneumonia.
 
Community acquired-pneumonia (CAP) still has high mor-
bidity and mortality worldwide despite advances in its man-
agement [1], resulting in an increasing number of hospital 
and intensive care unit (ICU) admissions [2, 3]. Patients with 
primary or secondary immunodeficiencies are more suscepti-
ble to pulmonary infections, and the occurrence of secondary 
immunodeficiencies is rising, caused by wider use of immuno-
suppressive medications [4].
Immunoglobulins (Igs) are fundamental mediators of 
humoral immunity by neutralization, opsonization, and 
phagocytosis of pathogens and by contributing to comple-
ment activation [5]. Deficiencies in this antibody-mediated 
immune system implicate a significant risk of recurrent infec-
tions, in particular those caused by encapsulated bacteria in 
the respiratory tract [6, 7]. In the acute phase of infectious 
diseases such as sepsis and severe influenza, low levels of Igs 
have been associated with an unfavorable outcome [8–10]. 
Correspondingly, an association between subnormal levels of 
Igs, predominantly total IgG and IgG1/2 subclasses, and dis-
ease severity has been reported in CAP and influenza A H1N1 
cohorts [11–13]. However, the relevance of Ig levels in relation 
to microbial etiology in CAP is less clear, although it is well 
known that IgG and in particular IgG2 are of major impor-
tance for the pulmonary defense against encapsulated bacteria 
[14, 15]. Furthermore, whereas an association has been estab-
lished in primary hypogammaglobulinemia, the significance of 
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a transient decrease in IgG/IgG2 levels during infections like 
CAP is more uncertain.
The complement system is a key part of immune defense, 
constituting a functional bridge between innate and humoral 
immunity [16]. Complement may be activated through 3 major 
pathways; the classical, lectin, and alternative, with consider-
able crosstalk between the pathways and with other branches of 
the immune system. Complement deficiencies have been asso-
ciated with increased susceptibility to bacterial infections [17]. 
The most prevalent deficiencies of the complement system are 
mannose-binding lectin (MBL) and complement component 2 
(C2), and it has been shown that individuals with C2 deficiency 
are more prone to infections and severe outcome in pneumo-
nia [17]. MBL is a soluble pattern recognition molecule, mainly 
exerting its effects through opsonization of pathogens and 
subsequent activation of the lectin complement pathway [18]. 
Genetically determined MBL deficiency is very prevalent, as 
complete deficiency affects 5% to 10% and low levels are seen in 
up to 30% of the Caucasian population [19]. With the exception 
of patients with cystic fibrosis [20] and, potentially, common 
variable immunodeficiency (CVID) [21], the significance of 
MBL deficiency in relation to CAP remains unclear.
We have previously reported that by using extended diagnos-
tics, a high microbial yield was achieved in a well-defined co-
hort of patients with CAP [22]. The objective of this study was 
to assess the presence of low Ig levels and decreased activation 
of the 3 major complement activation pathways at hospital ad-
mission and, if present, examine their association to microbial 
etiology, disease severity, and short-term and long-term out-
come. We hypothesized that low Ig levels, especially low IgG2, 
and decreased complement activation at admission would be 
associated with bacterial etiology and unfavorable outcome 
in CAP.
MATERIALS AND METHODS
Study Population and Design
The study was performed in an acute care 270-bed general 
hospital in Drammen, Vestre Viken Hospital Trust, in South-
Eastern Norway between January 1, 2008, and January 31, 2011; 
267 patients aged ≥18  years admitted with suspected pneu-
monia to the Department of Internal Medicine were consecu-
tively included. Patients were screened for eligibility within the 
first 48 hours of hospital admission by determining presence 
of CAP criteria, defined by (i) a new pulmonary infiltrate on 
chest radiograph, (ii) rectal temperature >38.0°C, and (iii) at 
least 1 of the following symptoms or signs: cough (productive 
or nonproductive), dyspnea, respiratory chest pain, crackles, 
or reduced respiratory sounds. If the chest radiographic exam-
ination uncovered noninfectious causes such as pulmonary 
infarction, tumor, or bronchiectasis, or if the patient had been 
hospitalized within the past 2 weeks, the patient was excluded 
from the study.
In the current study, patients with missing Ig and comple-
ment analyses at hospital admission (n  =  10) were excluded, 
leaving a sample of 257 (ie, analysis cohort). (The inclusion 
process is summarized in Supplementary Appendix.) Patients 
were invited to an outpatient follow-up approximately 6 weeks 
after hospital discharge (convalescent phase, n  =  220). When 
analyzing associations with long-term outcome, patients who 
died were considered responders at their death dates, and those 
who survived after the closing date were considered censored; 
patients who died within 30  days after hospital admission 
(n = 10) were excluded. Patients lost to follow-up were censored 
at the time of last contact.
Of the 257 patients in this study, 45 were considered im-
munocompromised. An immunocompromised host included 
the occurrence of (i) primary or secondary immunodeficiency, 
defined as antibody deficiency, human immunodeficiency virus 
(HIV), organ transplant, and/or receiving chemotherapy and/
or radiation therapy within the past 3 months; (ii) active malig-
nancy, defined as any cancer except basal—or squamous—cell 
cancer of the skin that was active at the time of presentation 
or diagnosed within 1  year of presentation; or (iii) immuno-
suppressive drug use, defined as any use of systemic steroids, 
Azathioprine, TNF inhibitor, Cyclosporine, Cyclophosphamide, 
or Methotrexate within the past 3 months.
All patients provided written informed consent. The study 
was approved by the Regional Committee for Medical and 
Health Research Ethics in South-Eastern Norway (ref. number 
S-06266a), and a waiver of consent was obtained from the com-
mittee to link patient data to death certificates (2012/467 A).
Data Collection and Definitions
Baseline data collection and definitions have been described 
elsewhere [22, 23]. In brief, demographic, clinical, and labora-
tory data were collected within 48 hours of admission. The 
mean time from hospital admission to study inclusion was 
0.6  ±  0.5  days, and 250 of 257 (97%) patients were included 
within 24 hours. The microbial etiology of CAP was established 
by use of comprehensive microbiological testing (ie, bacterial 
cultures, serology, urinary antigen tests, and polymerase chain 
reaction [PCR]).
Blood Sampling
Blood samples were obtained at hospital admission and at the 
scheduled 6-week follow-up, with serum and plasma samples 
drawn into pyrogen-free vacutainer tubes. Tubes for plasma 
samples contained ethylenediaminetetraacetic acid (EDTA) 
as anticoagulant. Serum or plasma was separated from whole 
blood within 60 minutes by refrigerated centrifugation at 2000 g 
for 12 minutes and stored in several aliquots at –80ºC. Samples 
were thawed only once.
Ig and Complement Analyses
Serum levels of IgM, IgA, IgG, and IgG subclasses (IgG1, 
IgG2, IgG3, IgG4) at hospital admission were quantified by 
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immunonephelometry (BN ProSpec nephelometer, Siemens AG, 
Germany, and Cobas 8000 analyzer, Roche AG, Switzerland). 
The reference values are given in Supplementary Appendix. In 
patients with levels of IgG or IgG2 below reference range at 
hospital admission, samples from the 6-week follow-up were 
analyzed.
Complement deficiencies were screened in serum with a 
total complement activity enzyme-linked immunosorbent 
assay (ELISA; Complement system Screen, Wieslab, Euro 
Diagnostica, Malmö, Sweden). The method includes classical 
pathway (CP), lectin pathway (LP), and alternative pathway 
(AP) activity with a common readout for terminal pathway ac-
tivity and has been described in detail previously [24]. The val-
ues are given in percentage related to a standard serum defined 
to contain 100% activity. The reference ranges are given in the 
Figure 2 legend. Patients with indications of complement defi-
ciency from the screening were further analyzed for the com-
plement proteins described below.
MBL was quantified using an ELISA described in detail pre-
viously [19]; low levels were defined as <50  ng/mL. C1q and 
C2 were quantified at Region Skåne, Lund, Sweden, and C3 and 
C4 at Oslo University Hospital, Oslo, Norway, using standard 
immunochemical techniques.
In brief, mannose-binding lectin–associated serine protease 
1 and 2 (MASP-1 and MASP-2, respectively) deficiencies were 
identified by genotyping for MASP1 G426E (rs28945068) and 
MASP2 D120G (rs72550870), while analysis of MASP-2 bind-
ing to MBL or ficolins was performed in serum with an assay 
from Hycult Biotech (HM2190-IA, Uden, the Netherlands) [25, 
26]. Plasma levels of MASP-2 were quantified by an ELISA kit 
(Hycult Biotech), with a reference range of 170–1196 ng/mL.
Outcome Measures
Based on the etiology, patients were categorized into 4 groups: 
(i) bacterial, (ii) viral, (iii) viral-bacterial, and (iv) unknown. 
In addition, patients with Streptococcus pneumoniae or 
Haemophilus influenzae were studied separately. Disease sever-
ity was evaluated by the validated CURB-65 scoring system 
[27]; patients with a CURB-65 score of <3 were classified into a 
low-risk group and ≥3 into a high-risk group. Short-term out-
come was defined as a composite end point of ICU admission 
and 30-day mortality [28]. Long-term outcome was defined as 
5-year all-cause mortality.
Statistical Analysis
Categorical variables were expressed as counts (percentages), 
and continuous variables were presented as mean (standard 
deviation) for normally distributed data or median (25th–75th 
percentiles) for visually skewed data. Continuous variables were 
analyzed using a t test, and comparison of categorical variables 
were compared using the χ2 test or 1-way ANOVA, where ap-
propriate, whereas Tukey’s test was performed for post hoc test 
of differences between pair of groups. Univariate and adjusted 
logistic regressions were used to assess the association be-
tween Ig or complement parameters and short-term outcome. 
Adjusted Cox regression analysis was used to assess the asso-
ciation between Ig or complement parameters and long-term 
outcome. A  2-sided P value <.05 was considered significant. 
Statistical analyses were performed using STATA, version 14.0, 
for Windows (Stata Corp LP, College Station, TX) and SPSS, 
version 23.0, for Windows (IBM Corp, Armonk, NY).
RESULTS
Ig Levels Below Reference Range
At hospital admission, 87 (34%) patients had levels below the 
reference range of at least 1 Ig (IgM, IgA, IgG, IgG1, IgG2, IgG3, 
or IgG4), with low IgG2 levels as the most prevalent finding (55 
patients/21%) (Figure  1). At the 6-week follow-up, IgG levels 
remained low in more than one-third of patients with sub-
normal levels at admission (12 patients, 40%). In particular, 
39 out of the 50 (78%) patients with low IgG2 at admission (2 
deceased, 3 missing samples) had levels below the reference 
range at the 6-week follow-up (Figure 1). We found no increase 
in comorbidities (cardiovascular disease [CVD], chronic ob-
structive pulmonary disease [COPD], autoimmune disease, 
diabetes mellitus, renal disease, neurological disease) among 
patients with low IgM, IgA, IgG, or IgG2 levels compared with 
the rest of the study population.
Ig Levels in Relation to Microbial Etiology
Low levels of any Ig at hospital admission were not related to 
a specific group of microbial etiology. However, serum levels 
of IgG differed significantly between the groups of etiology 
(P =  .027), with lower levels seen in bacterial than viral CAP 
(P = .023). For IgA, IgM, or any of the IgG subclasses, no rela-
tion to microbial etiology was seen (Table 1). Additionally, in 
patients with low levels of any Ig, CAP caused by encapsulated 
bacteria (S. pneumoniae and H. Influenzae) did not occur more 
frequently (P = .734).
Ig Levels in Relation to Disease Severity, Short-term Outcome, and Long-
term Outcome
Patients with low IgG or IgG2 at both time points did not pres-
ent with a higher CURB-65 severity score (P = .594) than other 
CAP patients. Moreover, there were no differences in Ig levels 
between patients with high (≥3) vs low (< 3) CURB-65 severity 
score (Table 2).
In all, 39 (15%) patients were survivors requiring ICU admis-
sion, while 10 (4%) patients died within 30  days of hospital 
admission. In univariate logistic regression analysis, Igs were 
not associated with an adverse short-term outcome when 
assessed as continuous variables (Table 3). Similarly, Igs below 
the reference range were not associated with an adverse short-
term outcome (Table 3).
Excluding patients who died within 30  days of hospital 
admission, 5-year mortality was 26% (65/246 patients, 1 lost 
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to follow-up). In age- and gender-adjusted Cox regression ana-
lysis, low levels of Igs were not associated with increased 5-year 
mortality (Supplementary Table  2). Adjustment for clinically 
significant comorbidities (CVD, COPD, active malignancy, and 
renal disease) did not affect results for disease severity, short-
term outcome, or long-term outcome.
Ig Results Excluding Immunocompromised Patients
Forty-five patients were defined as immunocompromised at 
study inclusion, leaving 212 patients in the study population 
when excluding these. In this assumed nonimmunocompro-
mised group, Ig levels at hospital admission differed signifi-
cantly between groups of microbial etiology for IgA (P = .048) 
and IgG2 (P  =  .021), with lower levels seen in bacterial than 
in viral-bacterial CAP for IgA (mean 2.55  ±  1.13  g/L vs 
3.34 ± 2.13 g/L, P = .039) and in bacterial vs viral CAP for IgG2 
(mean 2.51 ± 0.99 g/L vs 3.22 ± 1.45 g/L, P = .018). By contrast, 
low levels of any Ig were not associated with a higher CURB-
65 severity score. The number of adverse outcomes in this sub-
group was too low to perform outcome analyses.
Complement Deficiencies
Screening of serum samples documented 55 (21%) patients 
with low or undetectable lectin pathway activity, of which 3 also 
had a defective classical pathway activity (Figure 2). One of the 
3 patients had an MBL deficiency, was quantified for C1q, and 
had only a slightly reduced level. The other 2 had normal MBL 
and were quantified for C2 and C4, both with normal levels. 
Abnormalities in functional activity of the alternative pathway 
were not observed in our patient cohort (Figure 2).
MASP-2 Deficiency
One patient with a lectin pathway deficiency, normal MBL lev-
els (1134 ng/mL), and normal classical and alternative pathway 
activity was found to be homozygote MASP-2 deficient. MASP-2 
in serum did not form complexes with MBL or ficolins. Protein 
quantification of MASP-2 was in accordance with a defect, being 
63 and 29 ng/mL at hospital admission and 6-week follow-up, 
respectively, well below the reference range of 170–1196  ng/
mL. The patient was a previously healthy female aged 66 years 
without tendency to infection. The CURB-65 severity score at 
Table 1. Serum Immunoglobulin Levels (g/L) and Number of Patients With Serum Immunoglobulin Levels Below Reference Range at Hospital Admission 
in 257 Hospitalized Patients With Community-Acquired Pneumonia, Stratified by Etiology
Total
(n = 257)
Bacterial
(n = 73)
Viral-Bacterial
(n = 49)
Viral
(n = 39)
Unknown
(n = 96) P
IgM 0.86 ± 0.53 0.91 ± 0.59 0.84 ± 0.51 0.81 ± 0.41 0.95 ± 0.66 .657
IgA 2.83 ± 1.64 2.57 ± 1.09 3.16 ± 2.09 2.91 ± 1.82 2.43 ± 1.25 .139
IgG 9.08 ± 2.87 8.48 ± 2.71 9.26 ± 2.82 9.97 ± 3.04 8.72 ± 2.81 .027
IgG1 6.44 ± 2.53 6.01 ± 2.14 6.51 ± 2.51 7.16 ± 3.06 6.25 ± 2.29 .071
IgG2 2.70 ± 1.23 2.49 ± 1.10 2.81 ± 1.18 2.96 ± 1.46 2.49 ± 1.22 .123
IgG3 0.45 ± 0.31 0.44 ± 0.25 0.48 ± 0.37 0.46 ± 0.33 0.38 ± 0.23 .764
IgG4 0.55 ± 0.55 0.56 ± 0.56 0.51 ± 0.40 0.59 ± 0.68 0.57 ± 0.60 .762
IgG < ref. rangea 30 (100) 13 (36.7) 3 (10.0) 3 (10.0) 11 (43.3) .099
IgG2 < ref. rangea 55 (100) 17 (30.9) 6 (10.9) 7 (12.7) 25 (45.5) .313
Data are presented as means and ± standard deviation or No. (%). Group comparison performed with 1-way analysis of variance or χ2 test as appropriate. Patients with unknown etiology 
excluded from statistical analysis.
Abbreviations: Ig, immunoglobulin.
aAssessed as dichotomous variables.
60
40
29
9
30
55
Ig levels below reference range
39
7 7
Admission
6 weeks
4 6
12
3
7
20P
at
ie
nt
s, 
N
o.
0
IgM IgA IgG IgG1 IgG2 IgG3 IgG4
Figure 1. Patients with serum immunoglobulin levels below reference range at hospital admission and 6-week follow-up in 257 hospitalized patients with communi-
ty-acquired pneumonia. Data are presented as numbers. Only patients with low IgG or IgG2 at hospital admission were analyzed at 6-week follow-up. Abbreviation: Ig, 
immunoglobulin.
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admission was 1.  She was treated with intravenous antibiotics 
at a general ward for 5 days before discharge. The microbial eti-
ology of CAP was not identified.
MBL Deficiency in Relation to Microbial Etiology, Disease Severity, and 
Outcome
MBL-deficient serum samples were not related to microbial 
etiology, disease severity, or short-term or long-term outcome 
(Supplementary Table  3, A–D). A  similar pattern was seen 
when excluding immunocompromised patients, rendering 
31/212 (15%) patients with MBL deficiency (data not shown). 
Adjustment for clinically significant comorbidities (CVD, 
COPD, active malignancy, and renal disease) did not affect 
results for disease severity, short-term outcome, or long-term 
outcome.
DISCUSSION
In the present study, admission Ig levels below reference range 
were not associated with a specific group of microbial etiology 
in CAP, but IgG and IgG2 levels were significantly lower in bac-
terial than in viral CAP. Second, Ig levels below the reference 
range at hospital admission were not associated with disease se-
verity, short-term outcome, or long-term outcome. Third, MBL 
deficiency was not associated with microbial etiology, disease 
severity, or outcome measures.
Even though admission Ig levels below the reference range 
were not associated with a specific microbial etiology in our 
study, IgG levels were significantly lower in bacterial than in 
viral CAP, and when excluding immunocompromised patients, 
we found lower levels of IgG2 in bacterial vs viral CAP. Still, the 
IgG2 associations with bacterial CAP in the present cohort may 
be regarded as modest, and therefore in line with results from 
an Australian CAP study [11], where no single pathogen was 
associated with low IgG subclass levels, illustrating an uncertain 
impact of IgG2 deficiency. Antibodies to polysaccharide anti-
gens of encapsulated bacteria are largely, but not entirely, of the 
IgG2 subclass, while antibodies to protein antigens of viruses 
are IgG1 and IgG3 [29]. Previously, increased susceptibility to 
infections caused by encapsulated bacteria in patients with low 
IgG2 has been demonstrated [14, 15, 30], suggesting that inher-
ently IgG2-deficient patients have a reduced ability to mount 
an antibody response to certain polysaccharide antigens, lead-
ing to an inadequate defense against invading pathogens like 
S. pnuemoniae and H. influenzae. Yet, an appropriate immune 
response may remain intact in patients with low IgG2 levels, as 
the cause of reduced levels remains unclear. Another possible 
reason for low IgG2 levels may be consumption of antibodies 
in the acute phase of CAP, with low levels subsequently seen at 
hospital admission.
The causes and clinical importance of our IgG and IgG2 find-
ings are therefore uncertain.
Several recent studies have reported an association between 
low Ig levels, disease severity, and unfavorable outcome in 
patients with sepsis [8]. In CAP, however, this association has 
not been explored to the same extent. Feldman et al. could not 
find any differences in IgG subclass  levels between 66 non-
ICU and ICU patients with CAP [31]. By contrast, a recent 
Spanish study of 418 CAP patients showed a significant asso-
ciation between low Ig levels (IgG/IgG1) in patients with a 
CURB-65 severity score of 4 and 5, in ICU patients vs non-
ICU patients (IgG/IgG1/IgG2), and with 30-day mortality 
(IgG/IgG1/IgG2) [13]. Low levels of IgG2 have been observed 
in patients with severe H1N1 influenza in China [32] and 
Australia [10, 11]. Of note, in the Chinese study, the lowest 
IgG2 levels were seen in seriously ill influenza patients with a 
bacterial co-infection [32]. In our study, low serum levels of 
Igs at admission were associated neither with disease severity 
Table  2. Serum Immunoglobulin Levels (g/L) or Number of Patients 
With Low Immunoglobulin Levels at Hospital Admission Stratified by 
CURB-65 <3 vs CURB-65 ≥3 in 257 Hospitalized Patients With Community-
Acquired Pneumonia
Immunoglobulin
CURB-65 < 3
(n = 157)
CURB-65 ≥3
(n = 95) P
IgM 0.91 ± 0.53 0.88 ± 0.66 .737
IgA 2.64 ± 1.67 2.74 ± 1.19 .610
IgG 8.74 ± 2.88 9.17 ± 2.77 .249
IgG1 6.19 ± 2.54 6.56 ± 2.22 .241
IgG2 2.59 ± 1.23 2.67 ± 1.23 .601
IgG3 0.42 ± 0.24 0.44 ± 0.35 .454
IgG4 0.53 ± 0.54 0.59 ± 0.59 .409
IgG < ref. rangea 20 (66.7) 10 (33.3) .690
IgG2 < ref. rangea 35 (64.8) 19 (35.2) .752
Data presented as means and ± standard deviation or No. (%). Group comparison per-
formed with t test or χ2 test, as appropriate. Data on CURB-65 severity score are missing 
in 5 patients. 
Abbreviations: CURB-65, Confusion, Urea, Respiratory rate, Blood pressure, Age ≥65; Ig, 
immunoglobulin.
aAssessed as dichotomous variables.
Table  3. Univariate Logistic Regression Analysis of Serum 
Immunoglobulin Levels at Hospital Admission and Association to ICU 
Admission/30-Day Mortality in 257 Hospitalized Patients With Community-
Acquired Pneumonia
Immunoglobulins OR (95% CI) P
IgM 1.16 (0.69–1.93) .579
IgA 0.95 (0.77–1.18) .632
IgG 0.94 (0.84–1.06) .315
IgG1 0.99 (0.87–1.12) .843
IgG2 0.85 (0.64–1.11) .232
IgG3 0.99 (0.33–3.03) .993
IgG4 1.07 (0.63–1.82) .811
IgG < ref. rangea 1.64 (0.68–3.94) .268
IgG2 < ref. rangea 1.42 (0.69–2.91) .340
Abbreviations: CI; confidence interval; ICU, intensive care unit; Ig, immunoglobulin; OR, 
odds ratio.
aAssessed as dichotomous variables.
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nor with ICU admission and 30-mortality. The low number 
of severely ill patients may have influenced our observations 
regarding outcome. Nonetheless, the relationship between low 
admission Ig levels and adverse short-term outcome does not 
seem to be as close in CAP as in sepsis, at least not in patients 
with a nonsevere clinical course.
Despite the considerable morbidity in primary hypogam-
maglobulinemia, especially recurrent respiratory infections [6], 
the impact on the long-term outcome of a transient decrease in 
Igs during infections like pneumonia is not clear. In the present 
cohort, we did not find significant associations between low lev-
els of Igs at hospital admission and 5-year all-cause mortality, 
suggesting a less important role of low admission Ig levels per 
se on long-term immune responses.
Although deficiency of the pattern recognition molecule 
MBL has been associated with respiratory infections in cystic fi-
brosis [20] and CVID [21], a consistent predisposition to pneu-
monia in MBL-deficient or -insufficient patients has not been 
documented. A  meta-analysis indicated that MBL-deficient 
patients were predisposed to invasive pneumococcal infections 
[33], but in 3 CAP studies of low MBL, including a more re-
cent meta-analysis, no associations to S. pneumoniae or other 
pathogens in CAP have been found [34–36]. In our study popu-
lation, MBL deficiency was not associated with microbial eti-
ology. Consequently, our observations support the hypothesis 
that MBL deficiency is not an important factor for microbial 
vulnerability in CAP [37, 38].
A large Spanish study of 848 CAP patients found MBL 
insufficiency to be associated with severe sepsis, multiorgan 
dysfunction syndrome, ICU admission, and 90-day mortality, 
but not 28-day mortality [37]. In later studies, however, these 
findings have not been reproduced [36, 38]. Similarly, an associ-
ation between MBL deficiency and disease severity or outcome 
measures was not seen in our CAP cohort, but in our cohort 
fewer patients had a very high CURB-65 score and the short-
term mortality rate was fairly low. Thus, the study populations 
are not completely comparable. In conclusion, a link between 
MBL deficiency and CAP severity and outcome may exist, even 
though our results do not support an association.
MASP-2, a part of the MASP family, is a protease essential for 
activation of the lectin complement pathway by cleavage of C4 
and C2 [18]. Defects of MASP-2 have been suggested to be asso-
ciated with infectious diseases [39], but with an uncertain clin-
ical penetrance [40]. We identified a patient with a homozygous 
MASP-2 deficiency, to our knowledge the first case described in 
Norway. This patient was without tendency to recurrent infec-
tions and did not present with a severe form of CAP, in accord-
ance with previous findings [37].
Limitations
The following limitations should be considered. First, our study 
was performed at a single hospital, thereby possibly limiting its 
generalizability. Second, blood samples were not obtained be-
yond the 6-week follow-up; thus we do not know the time frame 
of the decrease in IgG/IgG2 levels in 39 patients in this CAP 
cohort. Third, the outcome measure short-term outcome was 
defined as a composite of ICU admission and 30-day mortality. 
A majority of patients (39/49, 80%) were categorized with the 
softer ICU survivor outcome parameter.
Conclusion
In summary, neither low admission immunoglobulin levels nor 
MBL deficiency was associated with microbial etiology, disease 
severity, short-term outcome, or long-term outcome in hospi-
talized patients with CAP.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online (http://ofid.oxfordjournals.org).
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Figure 2. Serum total complement activity for the classical pathway (CP), alternative pathway (AP), and lectin pathway (LP) at hospital admission in 257 hospitalized 
patients with community-acquired pneumonia. Values are given in percentage related to a standard serum defined to contain 100% activity. Low levels were defined as <10% 
activity for CP, <10% for AP, and <10% for LP.
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